BARDA is partnering with Chrysalis BioTherapeutics to continue development of TP508 as a nuclear countermeasure


WEB ANNOUNCEMENT
About Image

BARDA and Chrysalis Biotherapeutics, Inc. have exercised options under their current contract to expand their partnership and continue the development of TP508 (Chrysalin) as a countermeasure to address injuries resulting from a nuclear event. Chrysalis will conduct safety studies and additional activities required to request emergency use authorization from the U.S. Food and Drug Administration and approval under the FDA Animal Rule TP508 is a potential first-in-class countermeasure to prevent injury and death from ionizing radiation exposure. The therapeutic candidate may mitigate vascular damage, inhibit hemorrhage, reduce inflammation, and reverse acute tissue damage induced by radiation.

TP508 is a peptide (one or more amino acids that make up proteins in the human body) derived from the larger thrombin protein that is normally released at the point of injury to stimulate vascular and stem cell repair and to regenerate damaged tissue. Radiation exposure can have acute and delayed effects including damage to blood vessel that make up the body’s circulatory system, leading to inflammation, coagulopathies (excessive bleeding or clotting), sepsis, and multi-organ failure. This novel peptide drug restores vascular function by activating stem cells and stimulating endothelial cells (the thin layer of cells that line the inside of the heart and blood vessels). By enhancing nitric oxide signaling, the drug may also help reduce inflammation, accelerate DNA repair, and prevent coagulopathies.

Together, these effects of TP508 could reduce injury, illness, death, and delayed consequences from acute radiation exposure.

About Chrysalis BioTherapeutics, Inc.:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Chrysalis BioTherapeutics, Inc. was established in 2012 to develop and commercialize safe and effective drugs to save lives and improve quality of life. Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure.

Last Updated: November 30, 2020
Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov